WE CLAIM:

1. A humanized antibody that specifically binds to VT2 and/or VT2 variant

2. A humanized antibody that specifically binds to the B subunit of VT2 and/or the B subunit of VT2 variant.

3. The humanized antibody of claim 1 that neutralizes VT2 and/or VT2 variant.

4. The humanized antibody of claim 2 that neutralizes VT2 and/or VT2 variant.

5. A humanized antibody that is a humanized form of mouse antibody VTm1-1, the mouse antibody being characterized by a light chain variable region shown in Fig. 1B and a heavy chain variable region shown in Fig. 1A.

6. An antibody that competes with mouse antibody VTm1-1 for specific binding to VT2 and/or VT2 variant.

7. A humanized antibody of any of claims 1-6 comprising complementarity determining regions from the mouse VTm1-1 antibody and heavy and light chain variable region frameworks from the human GF4 antibody heavy and light chain frameworks, provided that at least one position selected from the group consisting of L49, H29, H30, H49 and H98, is occupied by the amino acid present in the equivalent position of the mouse VTm1-1 antibody heavy or light chain variable region framework, which humanized antibody specifically binds to verotoxin II with an affinity constant between 10^7 M^{-1} and ten-fold the affinity of the mouse VTm1-1 antibody.

8. The humanized antibody of claim 7, provided that each position selected from the group consisting of L49, H29, H30, H49 and H98 is occupied by the amino acid present in the equivalent position of the mouse VTm1-1 antibody heavy or light chain variable region framework.

9. The humanized antibody of claim 8, provided that at least one position selected from the group L3, L4, L19, L76, L79, L85, H1, H4, H5, H79, H89 and H93 is occupied by an amino acid present in the equivalent position of a human antibody heavy or light chain consensus sequence.

10. The humanized antibody of claim 9, provided that each position selected from the group L3, L4, L19, L76, L79, L85, H1, H4, H5, H79, H89 and H93 is occupied by an amino acid present in the equivalent position of a human antibody heavy or light chain consensus sequence.

11. The humanized antibody of any of claims 1-6 comprising a heavy chain variable region shown in Fig. 2A and a light chain variable region shown in Fig. 2B provided that one or more positions selected from the group consisting of L49, H29, H30, H49, H98, L3, L4, L19, L76, L79, L85, H1, H4, H5, H79, H89 and H93 may be substituted as shown in Tables 2 and 3.

12. The humanized antibody of any of claims 1-6, comprising a heavy chain variable region shown in Fig. 2A and a light chain variable region shown in Fig. 2B.

13. The humanized antibody of any of claims 1-6, comprising a humanized heavy chain having at least 85% identity with the humanized heavy chain shown in Fig. 2A and a humanized light chain having at least 85% sequence identity with the humanized light chain showing in Fig. 2B, provided that at least one position selected from the group consisting of

L49, H29, H30, H49 and H98, is occupied by the amino acid present in the equivalent position of the mouse VTm1-1 antibody heavy or light chain variable region framework.

14. The humanized antibody of any of claims 1-6, wherein the antibody comprises two pairs of light/heavy chain dimers, wherein each chain comprises a variable region and a constant region.

15. The humanized antibody of any of claims 1-6, which is a Fab fragment or a $F(ab')_2$.

16. The humanized antibody of any of claims 1-6 in purified form.

17. The humanized antibody of any of claims 1-6, which has an IgG_1 immunoglobulin isotype.

18. A method of producing humanized VTm1-1 antibody, comprising culturing a cell line, which encodes heavy and light chain chains of the humanized antibody of any of claims 1-6, whereby the humanized antibody is expressed; and recovering the humanized antibody expressed by the cell line.

19. The method of claim 18, further comprising mixing the antibody with a pharmaceutically acceptable carrier to produce a pharmaceutical composition.

20. A pharmaceutical composition comprising the humanized antibody of any of claims 1-6 and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising the humanized antibody of claim 12 and a pharmaceutically acceptable carrier.

22. A method of treating a patient suffering or at risk of toxic effects from a verotoxin, comprising administering to the patient an effective dosage of a human or humanized antibody that specifically binds to verotoxin II and/or verotoxin II variant.

23. The method of claim 22, wherein the antibody competes with mouse antibody VTm1-1 for specific binding to verotoxin II or verotoxin II variant.

24. The method of claim 22, wherein the humanized antibody specifically binds to VT2 and/or VT2 variant.

25. The method of claim 22, wherein the humanized antibody specifically binds to the B subunit of VT2 and/or VT2 variant.

26. The method of claim 22, wherein the humanized antibody specifically binds to VT2 and/or VT2 variant and neutralizes VT2 and/or VT2 variant.

27. The method of claim 22, wherein the humanized antibody specifically binds to the B subunit of VT2 and/or the B subunit of VT2 variant and neutralizes VT2 and/or VT2 variant.

28. The method of claim 22, wherein the antibody is a humanized antibody, which is a humanized form of the mouse VTm1-1 antibody.

29. The method of claim 22, wherein the antibody is a humanized antibody comprising a heavy chain variable region shown in Fig. 2A and a light chain variable region shown in Fig. 2B.

30. The method of claim 22, wherein the patient is infected with verotoxin producing *E. coli* and the antibody is administered therapeutically.

31. The method of claim 22, wherein the patient is at risk of infection by verotoxin producing *E. coli* and the antibody is administered prophylactically.

32. The method of claim 30, further comprising monitoring the patient for recovery from the toxic effects of verotoxin II or verotoxin II variant.

33. A cell line that produces the antibody of any of claim 1-6.